Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ischemic Heart Disease

Free Subscription Articles published in Lancet Retrieve available abstracts of 87 articles: HTML format

Single Articles

December 2025
1. KEDHI E, Hermanides RS, Dambrink JE, Singh SK, et al
   TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and c
   Lancet. 2025;404:2593-2602.
   PubMed     Abstract available
   
   
   
2. TARANTINI G, Cardaioli F
   TAVI and PCI: redefining treatment for aortic stenosis and complex coronary artery disease.
   Lancet. 2025;404:2492-2493.
   PubMed    
   
   
   August 2025
3. ROSSELLO X, Prescott EIB, Kristensen AMD, Latini R, et al
   beta blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.
   Lancet. 2025 Aug 29:S0140-6736(25)01592-2. doi: 10.1016/S0140-6736(25)01592.
   PubMed     Abstract available
   
   
   
4. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
   Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial.
   Lancet. 2025 Aug 28:S0140-6736(25)01529-6. doi: 10.1016/S0140-6736(25)01529.
   PubMed     Abstract available
   
   
   
5. BYRNE RA, Coughlan JJ
   Immediate or staged complete revascularisation in patients with ST segment elevation myocardial infarction.
   Lancet. 2025 Aug 28:S0140-6736(25)01680-0. doi: 10.1016/S0140-6736(25)01680.
   PubMed    
   
   
   
6. UDELL JA, Bahit MC, Campbell P, Butler J, et al
   Prevention of heart failure after acute myocardial infarction.
   Lancet. 2025 Aug 28:S0140-6736(25)01394-7. doi: 10.1016/S0140-6736(25)01394.
   PubMed     Abstract available
   
   
   
7. VERMA S, Leiter LA, Teoh H, Mancini GBJ, et al
   Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
   Lancet. 2025 Aug 28:S0140-6736(25)01633-2. doi: 10.1016/S0140-6736(25)01633.
   PubMed     Abstract available
   
   
   
8. GAUDINO M, Sandner S
   Evolocumab for prevention of coronary artery bypass failure: timing is everything.
   Lancet. 2025 Aug 28:S0140-6736(25)01718-0. doi: 10.1016/S0140-6736(25)01718.
   PubMed    
   
   
   
9. GUO X, Sun G, Xu Y, Zhou S, et al
   Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
   Lancet. 2025 Aug 28:S0140-6736(25)01391-1. doi: 10.1016/S0140-6736(25)01391.
   PubMed     Abstract available
   
   
   
10. VALGIMIGLI M, Choi KH, Giacoppo D, Gragnano F, et al
    Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis.
    Lancet. 2025 Aug 28:S0140-6736(25)01562-4. doi: 10.1016/S0140-6736(25)01562.
    PubMed     Abstract available
    
    
    
11. OSTROMINSKI JW, Cheng AYY, Nelson AJ, Neuen BL, et al
    Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01384-4. doi: 10.1016/S0140-6736(25)01384.
    PubMed     Abstract available
    
    
    
12. LAM CSP, Cader FA, Chew NWS, Chow CK, et al
    Tackling cardiovascular disease in the Asia-Pacific region: a new Lancet Commission.
    Lancet. 2025 Aug 25:S0140-6736(25)01494-1. doi: 10.1016/S0140-6736(25)01494.
    PubMed    
    
    
    
13. ROSSIGNOL P, Zannad F, Massy Z, Azizi M, et al
    Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
    Lancet. 2025;406:705-718.
    PubMed     Abstract available
    
    
    July 2025
14. VRINTS C, Andreotti F
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:335.
    PubMed    
    
    
    
15. ANDERSEN BK, Escaned J, Christiansen EH, Holm NR, et al
    QFR vs FFR for intermediate coronary stenosis - Authors' reply.
    Lancet. 2025;406:335-336.
    PubMed    
    
    
    
16. KOMAMURA K, Miyake H, Kobayashi K, Ishiki R, et al
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:334.
    PubMed    
    
    
    
17. ONUMA Y, Tsai TY, Sharif F, Wykrzykowska J, et al
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:334.
    PubMed    
    
    
    
18. ZHU Q, Cheng Y, Wang S
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:333-334.
    PubMed    
    
    
    
19. RODRIGUEZ-GRANILLO GA, Garcia-Garcia HM, Thierer J
    QFR vs FFR for intermediate coronary stenosis.
    Lancet. 2025;406:333.
    PubMed    
    
    
    June 2025
20. CONRAD N, Rahimi K, McMurray JJV, Casadei B, et al
    The changing spectrum of cardiovascular diseases.
    Lancet. 2025 Jun 9:S0140-6736(25)00990-0. doi: 10.1016/S0140-6736(25)00990.
    PubMed    
    
    
    
21. THE LANCET
    From innovation to impact in cardiovascular disease.
    Lancet. 2025;405:2023.
    PubMed    
    
    
    May 2025
22. LEE SJ, Kim BK
    Obicetrapib-ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease.
    Lancet. 2025 May 5:S0140-6736(25)00827-X. doi: 10.1016/S0140-6736(25)00827.
    PubMed    
    
    
    April 2025
23. HUANG C
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1463.
    PubMed    
    
    
    
24. VALGIMIGLI M, Hong SJ, Gragnano F, Hong MK, et al
    Ticagrelor monotherapy for acute coronary syndromes - Authors' reply.
    Lancet. 2025;405:1463-1464.
    PubMed    
    
    
    
25. APOSTOLOS A, Tsigkas G
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1462-1463.
    PubMed    
    
    
    
26. GUO C, Shan D, Liu Z, He F, et al
    Ticagrelor monotherapy for acute coronary syndromes.
    Lancet. 2025;405:1461-1462.
    PubMed    
    
    
    
27. ONIDA S, Davies AH
    Cardiovascular risk assessment in venous disease?
    Lancet. 2025;405:1141-1142.
    PubMed    
    
    
    March 2025
28. CHOI KH, Park YH, Lee JY, Jeong JO, et al
    Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00449-0. doi: 10.1016/S0140-6736(25)00449.
    PubMed     Abstract available
    
    
    
29. FEARON WF, Zimmermann FM, Ding VY, Takahashi K, et al
    Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00505-7. doi: 10.1016/S0140-6736(25)00505.
    PubMed     Abstract available
    
    
    
30. HU X, Zhang J, Yang S, Jiang J, et al
    Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease (FLAVOUR II): a multicentre, randomised, non-inferiority trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00504-5. doi: 10.1016/S0140-6736(25)00504.
    PubMed     Abstract available
    
    
    
31. KIRTANE AJ, Genereux P, Lewis B, Shlofmitz RA, et al
    Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00450-7. doi: 10.1016/S0140-6736(25)00450.
    PubMed     Abstract available
    
    
    
32. TAM DY, Lee G, Chikwe J
    Fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting: please mind the gap.
    Lancet. 2025 Mar 28:S0140-6736(25)00583-5. doi: 10.1016/S0140-6736(25)00583.
    PubMed    
    
    
    
33. COUGHLAN JJ, Byrne RA
    Orbital atherectomy for severely calcified coronary artery lesions.
    Lancet. 2025 Mar 28:S0140-6736(25)00572-0. doi: 10.1016/S0140-6736(25)00572.
    PubMed    
    
    
    
34. ROSSELLO X, Kristensen AMD
    Clopidogrel use in chronic coronary syndrome: a fragile lifelong choice.
    Lancet. 2025 Mar 28:S0140-6736(25)00562-8. doi: 10.1016/S0140-6736(25)00562.
    PubMed    
    
    
    
35. ZAMAN S, Wasfy JH, Kapil V, Ziaeian B, et al
    The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.
    Lancet. 2025 Mar 25:S0140-6736(25)00055-8. doi: 10.1016/S0140-6736(25)00055.
    PubMed    
    
    
    
36. THE LANCET
    Rethinking coronary artery disease: a call to action.
    Lancet. 2025 Mar 25:S0140-6736(25)00497-0. doi: 10.1016/S0140-6736(25)00497.
    PubMed    
    
    
    
37. CHANDRASHEKHAR Y, Mensah G, Narula J
    From coronary artery disease to atherosclerotic coronary artery disease: what is in a name?
    Lancet. 2025 Mar 25:S0140-6736(25)00563-X. doi: 10.1016/S0140-6736(25)00563.
    PubMed    
    
    
    
38. WILSON C
    Nancy Brown: using advocacy to advance cardiovascular health.
    Lancet. 2025;405:688.
    PubMed    
    
    
    February 2025
39. XU C
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:545.
    PubMed    
    
    
    
40. CHAN K, Neubauer S, Channon KM, Deanfield J, et al
    Inflammatory cardiovascular events and coronary artery disease - Authors' reply.
    Lancet. 2025;405:545-546.
    PubMed    
    
    
    
41. ZHAO K, Chen L, Sun Z
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:544.
    PubMed    
    
    
    
42. NURMOHAMED NS, Beverloo CYY, Kraaijenhof JM, Stroes ESG, et al
    Inflammatory cardiovascular events and coronary artery disease.
    Lancet. 2025;405:544-545.
    PubMed    
    
    
    January 2025
43. WILLIAMS MC, Wereski R, Tuck C, Adamson PD, et al
    Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
    Lancet. 2025;405:329-337.
    PubMed     Abstract available
    
    
    November 2024
44. LUSEBRINK E, Binzenhofer L, Adamo M, Lorusso R, et al
    Cardiogenic shock.
    Lancet. 2024;404:2006-2020.
    PubMed     Abstract available
    
    
    October 2024
45. ANDERSEN BK, Sejr-Hansen M, Maillard L, Campo G, et al
    Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.
    Lancet. 2024 Oct 29:S0140-6736(24)02175-5. doi: 10.1016/S0140-6736(24)02175.
    PubMed     Abstract available
    
    
    
46. BECKER LM, Swaans MJ
    Present and future of functional measurements in coronary revascularisation.
    Lancet. 2024 Oct 29:S0140-6736(24)02367-5. doi: 10.1016/S0140-6736(24)02367.
    PubMed    
    
    
    
47. ERLINGE D, Andersson J, Frobert O, Tornerud M, et al
    Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.
    Lancet. 2024 Oct 25:S0140-6736(24)02227-X. doi: 10.1016/S0140-6736(24)02227.
    PubMed     Abstract available
    
    
    
48. CAPODANNO D
    Coronary stenting with bioadaptors.
    Lancet. 2024 Oct 25:S0140-6736(24)02359-6. doi: 10.1016/S0140-6736(24)02359.
    PubMed    
    
    
    September 2024
49. THIELE H, Moller JE, Henriques JPS, Bogerd M, et al
    Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up.
    Lancet. 2024;404:1019-1028.
    PubMed     Abstract available
    
    
    
50. NORDESTGAARD BG, Langsted A
    Lipoprotein(a) and cardiovascular disease.
    Lancet. 2024 Sep 12:S0140-6736(24)01308-4. doi: 10.1016/S0140-6736(24)01308.
    PubMed     Abstract available
    
    
    August 2024
51. KRUMHOLZ HM, Geraldes F, Wilson C, Horton R, et al
    The Lancet-JACC collaboration: advancing cardiovascular health.
    Lancet. 2024;404:833-834.
    PubMed    
    
    
    
52. JENTZER JC, Hibbert B
    Optimal patient and mechanical circulatory support device selection in acute myocardial infarction cardiogenic shock.
    Lancet. 2024 Aug 30:S0140-6736(24)01588-5. doi: 10.1016/S0140-6736(24)01588.
    PubMed    
    
    
    
53. HONG SJ, Lee SJ, Lee SH, Lee JY, et al
    Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
    Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454.
    PubMed     Abstract available
    
    
    
54. MAMAS MA, Mintz GS
    Optical coherence tomography imaging for complex percutaneous coronary intervention.
    Lancet. 2024 Aug 30:S0140-6736(24)01593-9. doi: 10.1016/S0140-6736(24)01593.
    PubMed    
    
    
    
55. GAO C, He X, Ouyang F, Zhang Z, et al
    Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.
    Lancet. 2024 Aug 30:S0140-6736(24)01594-0. doi: 10.1016/S0140-6736(24)01594.
    PubMed     Abstract available
    
    
    
56. MCENTEGART MB, Kirtane AJ
    How feasible is a cage-free solution for de novo coronary artery disease?
    Lancet. 2024 Aug 30:S0140-6736(24)01696-9. doi: 10.1016/S0140-6736(24)01696.
    PubMed    
    
    
    
57. VALGIMIGLI M, Hong SJ, Gragnano F, Chalkou K, et al
    De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.
    Lancet. 2024 Aug 30:S0140-6736(24)01616-7. doi: 10.1016/S0140-6736(24)01616.
    PubMed     Abstract available
    
    
    
58. STEFANINI GG, Oliva A
    Is this the conclusive evidence for ticagrelor monotherapy in acute coronary syndromes?
    Lancet. 2024 Aug 30:S0140-6736(24)01678-7. doi: 10.1016/S0140-6736(24)01678.
    PubMed    
    
    
    
59. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    PubMed     Abstract available
    
    
    June 2024
60. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    PubMed     Abstract available
    
    
    
61. GAO Y, Li Z, Liu M, Tian J, et al
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2487.
    PubMed    
    
    
    
62. YU Z, Li G
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2487.
    PubMed    
    
    
    
63. ZEYMER U, Freund A, Hochadel M, Schneider S, et al
    VA-ECMO for infarct-related cardiogenic shock - Authors' reply.
    Lancet. 2024;403:2487-2488.
    PubMed    
    
    
    
64. LI Y
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2486.
    PubMed    
    
    
    
65. DALZELL JR
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2486.
    PubMed    
    
    
    
66. WANG G, Guan J, Liu Z
    VA-ECMO for infarct-related cardiogenic shock.
    Lancet. 2024;403:2485.
    PubMed    
    
    
    
67. KELLY P, Lemmens R, Weimar C, Walsh C, et al
    Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
    Lancet. 2024 Jun 7:S0140-6736(24)00968-1. doi: 10.1016/S0140-6736(24)00968.
    PubMed     Abstract available
    
    
    May 2024
68. CHAN K, Wahome E, Tsiachristas A, Antonopoulos AS, et al
    Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study.
    Lancet. 2024 May 29:S0140-6736(24)00596-8. doi: 10.1016/S0140-6736(24)00596.
    PubMed     Abstract available
    
    
    
69. COUTTS SB, Ankolekar S, Appireddy R, Arenillas JF, et al
    Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
    Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921.
    PubMed     Abstract available
    
    
    April 2024
70. FOLEY MJ, Rajkumar CA, Ahmed-Jushuf F, Simader FA, et al
    Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
    Lancet. 2024;403:1543-1553.
    PubMed     Abstract available
    
    
    
71. MONTI CB, Palmisano A
    Coronary sinus reducer: a new hope for refractory angina?
    Lancet. 2024;403:1514-1515.
    PubMed    
    
    
    
72. LI X, Ge Z, Kan J, Anjum M, et al
    Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial.
    Lancet. 2024 Apr 5:S0140-6736(24)00282-4. doi: 10.1016/S0140-6736(24)00282.
    PubMed     Abstract available
    
    
    
73. DEN DEKKER WK
    Is intravascular imaging the future of percutaneous coronary intervention?
    Lancet. 2024 Apr 5:S0140-6736(24)00430-6. doi: 10.1016/S0140-6736(24)00430.
    PubMed    
    
    
    
74. GE Z, Kan J, Gao X, Raza A, et al
    Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
    Lancet. 2024 Apr 5:S0140-6736(24)00473-2. doi: 10.1016/S0140-6736(24)00473.
    PubMed     Abstract available
    
    
    
75. STEINER-GAGER GM, Siller-Matula JM
    Abbreviated dual antiplatelet therapy after acute coronary syndrome.
    Lancet. 2024 Apr 5:S0140-6736(24)00586-5. doi: 10.1016/S0140-6736(24)00586.
    PubMed    
    
    
    
76. PARK SJ, Ahn JM, Kang DY, Yun SC, et al
    Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
    Lancet. 2024 Apr 4:S0140-6736(24)00413-6. doi: 10.1016/S0140-6736(24)00413.
    PubMed     Abstract available
    
    
    
77. BOROVAC JA
    Percutaneous coronary intervention for non-obstructive vulnerable plaques.
    Lancet. 2024 Apr 4:S0140-6736(24)00488-4. doi: 10.1016/S0140-6736(24)00488.
    PubMed    
    
    
    March 2024
78. RIDKER PM, Bhatt DL, Nissen SE
    Inflammation, infection, and cardiovascular risk - Authors' reply.
    Lancet. 2024;403:1025-1026.
    PubMed    
    
    
    
79. SHARMA S, Sharma R
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1024-1025.
    PubMed    
    
    
    
80. GOLDMAN M, Bondue A, Cogan E
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1023.
    PubMed    
    
    
    
81. GOLDSTEIN MR, Mascitelli L
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1023-1024.
    PubMed    
    
    
    
82. DROZD M, Cubbon R
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1022-1023.
    PubMed    
    
    
    
83. PAREEK A, Chandurkar N, Naidu K, Raut V, et al
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1022.
    PubMed    
    
    
    
84. STRANDBERG TE, Kovanen PT, Gylling H
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1021.
    PubMed    
    
    
    
85. LIN GM, Huang WC, Han CL
    Inflammation, infection, and cardiovascular risk.
    Lancet. 2024;403:1021-1022.
    PubMed    
    
    
    February 2024
86. LEE ZS, Ryan N
    Intravascular imaging in percutaneous coronary intervention.
    Lancet. 2024 Feb 21:S0140-6736(23)02686-7. doi: 10.1016/S0140-6736(23)02686.
    PubMed    
    
    
    
87. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
    Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
    Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge.